Arexvy contains a recombinant RSV glycoprotein F antigen combined with GSK’s proprietary AS01E adjuvant.

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...

Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core operating profit growth.

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Following various phone and smartwatch apps (Fitbits, fitness trackers, etc.), people have been focusing on taking 10,000 ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in second-quarter profit, supported by continued strength in its HIV and oncology ...

It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the first weeks since they ...

Vaccines Older Adults Really Need A measles booster? The shingles shot? Here's expert advice on which shots you should get—and when.

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that offered some respite after recent setbacks.

A measles booster? The shingles shot? Here's expert advice on which shots you should get—and when.By Hallie LevineDiseases ...